Yungjin Pharmaceutical Q1 2026 Preliminary: Slight Revenue Decline, Operating Loss Swing
-
Q1 2026 revenue of 63.7 billion KRW, down 0.5% YoY
-
Operating loss of 17.5 billion KRW, swinging from operating profit of 26.1 billion KRW in Q1 2025
-
Net loss of 22.8 billion KRW, swinging from profit
-
Preliminary figures subject to change after external audit review
KOSPI Filing Information
-
Filing: Preliminary Operating Results (Fair Disclosure)
-
Company: YUNGJIN PHARM (003520)
-
Submission: YUNGJIN PHARM. CO., LTD
-
Receipt: 05-06-2026
-
Under KRX KOSPI Market Division